Rohrmann K - Search Results

1

Targeted agents for the treatment of advanced renal cell carcinoma.

Staehler M, Rohrmann K, Haseke N, Stief CG, Siebels M. Staehler M, et al. Among authors: rohrmann k. Curr Drug Targets. 2005 Nov;6(7):835-46. doi: 10.2174/138945005774574498. Curr Drug Targets. 2005. PMID: 16305462 Review.

2

Immunotherapy in metastatic renal cell carcinoma.

Rohrmann K, Staehler M, Haseke N, Bachmann A, Stief CG, Siebels M. Rohrmann K, et al. World J Urol. 2005 Jul;23(3):196-201. doi: 10.1007/s00345-004-0470-4. Epub 2005 Apr 2. World J Urol. 2005. PMID: 15806434 Review.

3

Therapeutic approaches in metastatic renal cell carcinoma.

Staehler M, Rohrmann K, Bachmann A, Zaak D, Stief CG, Siebels M. Staehler M, et al. Among authors: rohrmann k. BJU Int. 2005 Jun;95(8):1153-61. doi: 10.1111/j.1464-410X.2005.05537.x. BJU Int. 2005. PMID: 15877725 Review. No abstract available.

4

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients.

Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, Beck J, Hofmann R, Kindler M, Kloepfer P, Stief C. Siebels M, et al. Among authors: rohrmann k. World J Urol. 2011 Feb;29(1):121-6. doi: 10.1007/s00345-010-0570-2. Epub 2010 May 30. World J Urol. 2011. PMID: 20512580 Clinical Trial.

5

[Complete remission of pulmonary metastasis from renal cell carcinoma through inhalation therapy with Interleukin-2 after unsuccessful systemic immunochemotherapy].

Rohrmann K, Schleypen J, Adam C, Hofstetter A, Siebels M. Rohrmann K, et al. Urologe A. 2004 Oct;43(10):1271-4. doi: 10.1007/s00120-004-0669-4. Urologe A. 2004. PMID: 15372156 German.

6

Symphysitis following transrectal biopsy of the prostate.

Adam C, Graser A, Koch W, Trottmann M, Rohrmann K, Zaak D, Stief C. Adam C, et al. Among authors: rohrmann k. Int J Urol. 2006 Jun;13(6):832-3. doi: 10.1111/j.1442-2042.2006.01417.x. Int J Urol. 2006. PMID: 16834675

7

Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes.

Schleypen JS, Von Geldern M, Weiss EH, Kotzias N, Rohrmann K, Schendel DJ, Falk CS, Pohla H. Schleypen JS, et al. Among authors: rohrmann k. Int J Cancer. 2003 Oct 10;106(6):905-12. doi: 10.1002/ijc.11321. Int J Cancer. 2003. PMID: 12918068

8

Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.

Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Gröne EF, Hohenfellner M, Haferkamp A, Pohla H, Schendel DJ, Falk CS, Noessner E. Schleypen JS, et al. Among authors: rohrmann k. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):718-25. doi: 10.1158/1078-0432.CCR-05-0857. Clin Cancer Res. 2006. PMID: 16467081

9

Cationic amphiphilic drugs enhance entry of lentiviral particles pseudotyped with rabies virus glycoprotein into non-neuronal cells.

Klintworth A, Nolden T, Westhaus S, Rohrmann K, David S, Manns MP, Finke S, Ciesek S, von Hahn T. Klintworth A, et al. Among authors: rohrmann k. Antiviral Res. 2015 Dec;124:122-31. doi: 10.1016/j.antiviral.2015.10.017. Epub 2015 Nov 2. Antiviral Res. 2015. PMID: 26542648

10

The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry.

Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, Pöhlmann S, Vondran FW, David S, Manns MP, Ciesek S, von Hahn T. Gehring G, et al. Among authors: rohrmann k. J Antimicrob Chemother. 2014 Aug;69(8):2123-31. doi: 10.1093/jac/dku091. Epub 2014 Apr 7. J Antimicrob Chemother. 2014. PMID: 24710028 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters